104 related articles for article (PubMed ID: 19913054)
1. Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies.
Sirskyj D; Weltzin R; Golshani A; Anderson D; Bozic J; Diaz-Mitoma F; Azizi A
J Virol Methods; 2010 Feb; 163(2):459-64. PubMed ID: 19913054
[TBL] [Abstract][Full Text] [Related]
2. Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype.
Mo C; Yamagata R; Pan A; Reddy J; Hazari N; Duke G
J Virol Methods; 2008 Jun; 150(1-2):63-9. PubMed ID: 18423899
[TBL] [Abstract][Full Text] [Related]
3. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.
Huber VC; McCullers JA
J Infect Dis; 2006 Mar; 193(5):677-84. PubMed ID: 16453263
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus.
Grund S; Adams O; Wählisch S; Schweiger B
J Virol Methods; 2011 Feb; 171(2):369-73. PubMed ID: 21146560
[TBL] [Abstract][Full Text] [Related]
5. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model.
Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M
Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959
[TBL] [Abstract][Full Text] [Related]
7. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.
Wang W; Butler EN; Veguilla V; Vassell R; Thomas JT; Moos M; Ye Z; Hancock K; Weiss CD
J Virol Methods; 2008 Nov; 153(2):111-9. PubMed ID: 18722473
[TBL] [Abstract][Full Text] [Related]
8. Design and optimization of a multiplex anti-influenza peptide immunoassay.
Drummond JE; Shaw EE; Antonello JM; Green T; Page GJ; Motley CO; Wilson KA; Finnefrock AC; Liang X; Casimiro DR
J Immunol Methods; 2008 May; 334(1-2):11-20. PubMed ID: 18329663
[TBL] [Abstract][Full Text] [Related]
9. An improved plaque reduction virus neutralization assay for human metapneumovirus.
de Graaf M; Herfst S; Schrauwen EJ; van den Hoogen BG; Osterhaus AD; Fouchier RA
J Virol Methods; 2007 Aug; 143(2):169-74. PubMed ID: 17420056
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
11. Serum antibodies against circulating influenza strains among vaccinated and unvaccinated general practitioners during two consecutive years (2002-2003).
Michiels B; Philips H; Coenen S; Denekens J; Van Royen P
Vaccine; 2006 Apr; 24(16):3145-52. PubMed ID: 16490288
[TBL] [Abstract][Full Text] [Related]
12. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay.
Gavrilov V; Orekov T; Alabanza C; Porika U; Jiang H; Connolly K; Pincus S
J Virol Methods; 2011 May; 173(2):364-73. PubMed ID: 21419169
[TBL] [Abstract][Full Text] [Related]
13. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
[TBL] [Abstract][Full Text] [Related]
15. [Microneutralization assay in the diagnosis of influenza infection].
Havlicková M; Jirincová H; Maresová V; Dzupová O; Limberková R
Epidemiol Mikrobiol Imunol; 2012 May; 61(1-2):9-14. PubMed ID: 22880259
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine.
Cheng LW; Huang SW; Huang LM; Chang LY; Shao PL; Kiang D; Wang JR
J Virol Methods; 2012 Jun; 182(1-2):43-9. PubMed ID: 22433514
[TBL] [Abstract][Full Text] [Related]
17. Human cell lines used in a micro neutralization test for measuring influenza-neutralizing antibodies.
Mittelholzer CM; Brokstad KA; Pauksens K; Jonsson R; Brytting M; Linde A
Scand J Immunol; 2006 Apr; 63(4):257-63. PubMed ID: 16623925
[TBL] [Abstract][Full Text] [Related]
18. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
19. Identification of a human monoclonal Fab with neutralizing activity against H3N2 influenza A strain from a newly constructed human Fab library.
Shibuya T; Yamashiro T; Masaike Y; Ohuchi M; Uechi G; Nishizono A
Microbiol Immunol; 2008 Mar; 52(3):162-70. PubMed ID: 18402598
[TBL] [Abstract][Full Text] [Related]
20. Neutralization titers against influenza A (H3N2) and influenza B viruses among a non-vaccinated population from Thailand.
Boonsathorn N; Kanai Y; Punjumpa J; Bai G; Chittaganpitch M; Petphuwadee U; Jampangern W; Sawanpanyalert P; Ikuta K; Teerasut C
Southeast Asian J Trop Med Public Health; 2012 May; 43(3):674-9. PubMed ID: 23077847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
